RAAP Cautions States Against Implementing 'Most Favored Nation' Drug Pricing Strategies

The Rare Access Action Project (RAAP) recently released a significant policy paper titled "Importing Most Favored Nation Pricing into States Is Not the Answer." This document critically examines the increasing tendency among U.S. states to consider international reference pricing models as solutions for prescription drug affordability. The study underscores potential dangers in importing Most Favored Nation (MFN) pricing benchmarks into state healthcare frameworks, indicating that such measures could inadvertently jeopardize patient access to vital medications while doing little to tackle the underlying issues surrounding drug affordability.

As states grapple with escalating prescription drug costs, many have begun relying on Prescription Drug Affordability Boards (PDABs) to analyze costly treatments and, in specific instances, set Upper Payment Limits (UPLs) on reimbursements. While these frameworks may aim to alleviate some financial burdens, RAAP's findings expose considerable risks. Specifically, the report suggests that integrating PDAB authority with MFN pricing could induce structural and operational complications within the U.S. healthcare system.

The essence of MFN pricing involves linking U.S. reimbursement rates to the lowest prices charged in other countries. This approach is flawed when adapted at the state level since international pricing models operate within fundamentally different healthcare landscapes that include centralized purchasing, constrained formularies, and access limitations – elements that starkly contrast the healthcare systems in the U.S.

Michael Eging, the Executive Director of RAAP, expressed, "States are correct to prioritize affordability, but the solutions need to align with the realities of healthcare delivery. Our research indicates that adopting MFN pricing within state reimbursement strategies could lead to disturbing consequences, such as supply disruptions, increased administrative hurdles, and deferred treatments for those most in need, especially individuals with rare diseases who already face restrictive options. It is crucial that affordability reforms simplify access to essential treatments rather than obstruct it."

The RAAP report details several critical observations:

1. The Operational Mismatch

MFN benchmarks often possess little relevance to the realities of U.S. drug procurement and distribution costs. When reimbursement thresholds fall below actual acquisition costs, it leads pharmacies and healthcare providers to either halt stocking or administering the impacted therapies.

2. Supply Chain Repercussions

Capping payments based on foreign prices might instigate alterations in distributor contracts and affect provider participation, ultimately causing treatment delays or interruptions, adversely affecting patient care.

3. Conflicts with Federal Policies

Implementation of MFN pricing guidelines may collide with the existing Medicaid Drug Rebate Program's "best price" stipulations, potentially creating comprehensive pricing implications that span beyond individual state policies.

4. Significant Impact on Rare Disease Patients

Those with rare illnesses often rely on specialized treatment centers and limited distribution networks. Thus, any disruptions in reimbursement can uniquely hinder their access to necessary therapies.

Jennifer Snow, a researcher from Apteka who contributed to the study, pointed out that "MFN pricing reveals merely the lowest observed price elsewhere, neglecting what reimbursement rate is sustainable within the U.S. healthcare landscape. Ignoring the complexities of economic distribution and federal rules could destabilize patient access rather than enhance affordability."

The report advocates for states to pursue affordability methods that are directly related to patient costs instead of resorting to MFN-based caps. Recommended strategies include redesigning benefits to minimize out-of-pocket expenses, enhancing transparency, establishing high-cost risk pools for managing rare diseases, and ensuring access safeguards as PDAB policies get implemented.

"In the end, the benchmark for policy success should focus on whether patients can consistently access the treatments they require," Eging concluded. "States have an opportunity to adopt affordability strategies that reinforce rather than weaken the systems upon which patients rely."

The complete report titled "Importing Most Favored Nation Pricing into States Is Not the Answer" can be accessed on the RAAP website at RAAP Website. RAAP is dedicated to collaborating with patient and life science communities to identify innovative policy solutions aimed at resolving access and coverage issues, primarily focusing on ensuring that patients with rare diseases receive the necessary care and treatments.